This trial will assess the efficacy and safety of the study drug in an at-risk patient population. Work on the study is expected to begin immediately. Covalent will provide multiple services including consulting on trial design and protocol development, and project and study site management.
“We are delighted to have been chosen by this new client to work on this phase II trial involving a novel cardiovascular agent,” said Covalent Group’s president and CEO. “If this trial is successful, it is anticipated that additional clinical research trials will be conducted by the Sponsor and that Covalent will be well positioned to participate in this potentially large development program.”